TTRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Turn Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$10.74+0.17 (+1.61%)
Close on Oct 19, 2026
- Market cap
- $319.92M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$5.68 (+112.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $319.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 465.76
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$8.45M
- EPS, diluted
- -$0.29
- Book value per share
- $0.02
- Diluted shares
- 30M
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
-$6.98M
Net income
-$8.45M
EPS, diluted
-$0.29
Reported periodTrailing twelve months